23,109 Shares in Bristol Myers Squibb Company $BMY Bought by Keudell Morrison Wealth Management

Keudell Morrison Wealth Management acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 23,109 shares of the biopharmaceutical company’s stock, valued at approximately $1,247,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Man Group plc grew its holdings in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after acquiring an additional 5,503,391 shares during the period. Two Sigma Investments LP grew its holdings in Bristol Myers Squibb by 530.6% during the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after acquiring an additional 4,588,601 shares during the period. Van ECK Associates Corp grew its holdings in Bristol Myers Squibb by 67.8% during the third quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock worth $444,682,000 after acquiring an additional 3,982,439 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Bristol Myers Squibb by 31.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock worth $669,012,000 after acquiring an additional 3,522,696 shares during the period. Finally, AQR Capital Management LLC grew its holdings in Bristol Myers Squibb by 56.0% during the third quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock worth $426,352,000 after acquiring an additional 3,396,041 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 1.8%

Shares of NYSE:BMY opened at $59.58 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock’s fifty day simple moving average is $58.47 and its 200-day simple moving average is $55.83. The company has a market capitalization of $121.67 billion, a P/E ratio of 16.74, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the prior year, the business earned $1.80 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by corporate insiders.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to roll out Claude Enterprise across its global operations, giving more than 30,000 employees access to AI tools aimed at speeding up drug discovery, development, manufacturing, and commercial work. Article: Bristol Myers Squibb Announces Strategic Agreement with Anthropic
• Positive Sentiment: The company said it will unveil new data at ASCO 2026, highlighting the strength of its oncology portfolio and next-generation pipeline, which could reinforce confidence in future cancer-drug growth. Article: Bristol Myers Squibb to Unveil New Data at ASCO 2026
• Neutral Sentiment: Market commentary continues to center on the balance between Bristol Myers Squibb’s pipeline potential and patent-expiration risks, keeping investor sentiment tied to upcoming data readouts and execution. Article: How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks

Analyst Ratings Changes

BMY has been the topic of several research reports. Piper Sandler reissued an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. UBS Group reissued a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Guggenheim reissued a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Cantor Fitzgerald upped their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Finally, Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.